Efficacy of Cilostazol Administration in Alzheimer’s Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study
This study tested the efficacy of the phosphodiesterase type III inhibitor cilostazol in Alzheimer’s disease patients with white matter lesions treated with donepezil in comparison with donepezil monotherapy using fluorodeoxyglucose ( 18 F) positron-emission tomography (FDG PET). A 24-week, randomiz...
Gespeichert in:
| Veröffentlicht in: | Neurotherapeutics 2019-04, Vol.16 (2), p.394-403 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 403 |
|---|---|
| container_issue | 2 |
| container_start_page | 394 |
| container_title | Neurotherapeutics |
| container_volume | 16 |
| creator | Lee, Jun-Young Lee, Haewoo Yoo, Hye Bin Choi, Jung-Seok Jung, Hee-Yeon Yoon, Eun Jin Kim, Hongrae Jung, Ye-Ha Lee, Ho-Young Kim, Yu Kyeong |
| description | This study tested the efficacy of the phosphodiesterase type III inhibitor cilostazol in Alzheimer’s disease patients with white matter lesions treated with donepezil in comparison with donepezil monotherapy using fluorodeoxyglucose (
18
F) positron-emission tomography (FDG PET). A 24-week, randomized, double-blind, placebo-controlled, parallel-group study was conducted. Thirty-six Alzheimer’s disease patients with white matter lesions who received donepezil (
n
= 18 each in the cilostazol and placebo groups) were enrolled. Participants underwent pre and post FDG PET imaging scans and three rounds of clinical and neuropsychological tests. The cilostazol group did not show a significant decrease of regional glucose metabolism; however, regional glucose metabolism was significantly decreased in the parietal and frontal lobes of the placebo group. The repeated measures ANOVA measuring differences in uptake change revealed that regional glucose metabolism in the left inferior frontal gyrus was significantly more preserved in the cilostazol group than that in the placebo group (
p
|
| doi_str_mv | 10.1007/s13311-018-00708-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6554387</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2179177360</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-e9101a0016219bbbe8849c62dd464630796fb084bb2f9e3d104845a456cfd3dc3</originalsourceid><addsrcrecordid>eNp9UcmO1DAUtBCIGQZ-gAOyxIVLwFtimwNSq2kWqREjMYij5SROx6MkbvwcmJ4TN76B3-NLcNPDsBw4eal69apUCN2n5DElRD4ByjmlBaGqyE-iiosb6JgqqQoppL6Z75rzQjLKj9AdgHNCSs61uo2OOJEVLYk-Rl9XXecb2-xw6PDSDwGSvQwDXrSjnzykaJMPE_YTXgyXvfOji9-_fAP83IOz4PBpxt2UAH_2qccfep8cfmNTchGvHeRReIoX-DSATzFMxWr0sP_FZ2EMm2i3_Q6_S3O7u4tudXYAd-_qPEHvX6zOlq-K9duXr5eLddEIKVLhNCXUEkIrRnVd104poZuKta2oRJVj6aqriRJ1zTrteEuJUKK0oqyaruVtw0_Qs4Pudq5H1zbZe7SD2UY_2rgzwXrzNzL53mzCJ1OVpeBKZoFHVwIxfJwdJJMjNW4Y7OTCDIYxlj0qVpJMffgP9TzMccrxDKNSUyl5tWexA6uJASC67toMJWbfszn0bHLP5mfP5iIPPfgzxvXIr2IzgR8IkKFp4-Lv3f-R_QFCjLdT</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2179177360</pqid></control><display><type>article</type><title>Efficacy of Cilostazol Administration in Alzheimer’s Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>SpringerNature Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Lee, Jun-Young ; Lee, Haewoo ; Yoo, Hye Bin ; Choi, Jung-Seok ; Jung, Hee-Yeon ; Yoon, Eun Jin ; Kim, Hongrae ; Jung, Ye-Ha ; Lee, Ho-Young ; Kim, Yu Kyeong</creator><creatorcontrib>Lee, Jun-Young ; Lee, Haewoo ; Yoo, Hye Bin ; Choi, Jung-Seok ; Jung, Hee-Yeon ; Yoon, Eun Jin ; Kim, Hongrae ; Jung, Ye-Ha ; Lee, Ho-Young ; Kim, Yu Kyeong</creatorcontrib><description>This study tested the efficacy of the phosphodiesterase type III inhibitor cilostazol in Alzheimer’s disease patients with white matter lesions treated with donepezil in comparison with donepezil monotherapy using fluorodeoxyglucose (
18
F) positron-emission tomography (FDG PET). A 24-week, randomized, double-blind, placebo-controlled, parallel-group study was conducted. Thirty-six Alzheimer’s disease patients with white matter lesions who received donepezil (
n
= 18 each in the cilostazol and placebo groups) were enrolled. Participants underwent pre and post FDG PET imaging scans and three rounds of clinical and neuropsychological tests. The cilostazol group did not show a significant decrease of regional glucose metabolism; however, regional glucose metabolism was significantly decreased in the parietal and frontal lobes of the placebo group. The repeated measures ANOVA measuring differences in uptake change revealed that regional glucose metabolism in the left inferior frontal gyrus was significantly more preserved in the cilostazol group than that in the placebo group (
p
< 0.005). Mean changes from baseline on the Mini-Mental State Exam, Alzheimer’s Disease Assessment Scale-cognitive subscale, Alzheimer’s Disease Cooperative Study-Activities of Daily Living Inventory, and the Clinical Dementia Rating Sum of Boxes did not differ between the two groups. In the cilostazol group, the increase of glucose metabolism correlated with the improvment of the Alzheimer’s Disease Assessment Scale-cognitive score. We conclude that cilostazol treatment added to donepezil may delay the decline in regional cerebral metabolism in Alzheimer’s disease with white matter lesions compared with donepezil monotherapy. In additon, our results verified the efficacy of cilostazol in improving or protecting cognitive function in Alzheimer’s disease through increased glucose metabolism. However, the long-term effect of cilostazol on cognitive function and Alzheimer’s disease modification must be tested in further studies with larger sample size and longer study period. Trial registration:
http://clinicaltrials.gov
: NCT01409564</description><identifier>ISSN: 1933-7213</identifier><identifier>ISSN: 1878-7479</identifier><identifier>EISSN: 1878-7479</identifier><identifier>DOI: 10.1007/s13311-018-00708-x</identifier><identifier>PMID: 30761509</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Activities of Daily Living ; Aged ; Aged, 80 and over ; Alzheimer Disease - diagnostic imaging ; Alzheimer Disease - drug therapy ; Alzheimer Disease - metabolism ; Alzheimer's disease ; Biomedical and Life Sciences ; Biomedicine ; Brain - diagnostic imaging ; Brain - drug effects ; Brain - metabolism ; Cilostazol - pharmacology ; Cilostazol - therapeutic use ; Clinical trials ; Cognition - drug effects ; Cognitive ability ; Dementia disorders ; Donepezil ; Double-Blind Method ; Double-blind studies ; Female ; Frontal gyrus ; Glucose - metabolism ; Humans ; Male ; Metabolism ; Neurobiology ; Neurology ; Neuroprotective Agents - pharmacology ; Neuroprotective Agents - therapeutic use ; Neuropsychological Tests ; Neurosciences ; Neurosurgery ; Original ; Original Article ; Patients ; Phosphodiesterase ; Positron emission tomography ; Substantia alba ; Tomography ; Treatment Outcome ; White Matter - diagnostic imaging ; White Matter - drug effects ; White Matter - metabolism</subject><ispartof>Neurotherapeutics, 2019-04, Vol.16 (2), p.394-403</ispartof><rights>The American Society for Experimental NeuroTherapeutics, Inc. 2019</rights><rights>Neurotherapeutics is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-e9101a0016219bbbe8849c62dd464630796fb084bb2f9e3d104845a456cfd3dc3</citedby><cites>FETCH-LOGICAL-c474t-e9101a0016219bbbe8849c62dd464630796fb084bb2f9e3d104845a456cfd3dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554387/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554387/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,41493,42562,51324,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30761509$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Jun-Young</creatorcontrib><creatorcontrib>Lee, Haewoo</creatorcontrib><creatorcontrib>Yoo, Hye Bin</creatorcontrib><creatorcontrib>Choi, Jung-Seok</creatorcontrib><creatorcontrib>Jung, Hee-Yeon</creatorcontrib><creatorcontrib>Yoon, Eun Jin</creatorcontrib><creatorcontrib>Kim, Hongrae</creatorcontrib><creatorcontrib>Jung, Ye-Ha</creatorcontrib><creatorcontrib>Lee, Ho-Young</creatorcontrib><creatorcontrib>Kim, Yu Kyeong</creatorcontrib><title>Efficacy of Cilostazol Administration in Alzheimer’s Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study</title><title>Neurotherapeutics</title><addtitle>Neurotherapeutics</addtitle><addtitle>Neurotherapeutics</addtitle><description>This study tested the efficacy of the phosphodiesterase type III inhibitor cilostazol in Alzheimer’s disease patients with white matter lesions treated with donepezil in comparison with donepezil monotherapy using fluorodeoxyglucose (
18
F) positron-emission tomography (FDG PET). A 24-week, randomized, double-blind, placebo-controlled, parallel-group study was conducted. Thirty-six Alzheimer’s disease patients with white matter lesions who received donepezil (
n
= 18 each in the cilostazol and placebo groups) were enrolled. Participants underwent pre and post FDG PET imaging scans and three rounds of clinical and neuropsychological tests. The cilostazol group did not show a significant decrease of regional glucose metabolism; however, regional glucose metabolism was significantly decreased in the parietal and frontal lobes of the placebo group. The repeated measures ANOVA measuring differences in uptake change revealed that regional glucose metabolism in the left inferior frontal gyrus was significantly more preserved in the cilostazol group than that in the placebo group (
p
< 0.005). Mean changes from baseline on the Mini-Mental State Exam, Alzheimer’s Disease Assessment Scale-cognitive subscale, Alzheimer’s Disease Cooperative Study-Activities of Daily Living Inventory, and the Clinical Dementia Rating Sum of Boxes did not differ between the two groups. In the cilostazol group, the increase of glucose metabolism correlated with the improvment of the Alzheimer’s Disease Assessment Scale-cognitive score. We conclude that cilostazol treatment added to donepezil may delay the decline in regional cerebral metabolism in Alzheimer’s disease with white matter lesions compared with donepezil monotherapy. In additon, our results verified the efficacy of cilostazol in improving or protecting cognitive function in Alzheimer’s disease through increased glucose metabolism. However, the long-term effect of cilostazol on cognitive function and Alzheimer’s disease modification must be tested in further studies with larger sample size and longer study period. Trial registration:
http://clinicaltrials.gov
: NCT01409564</description><subject>Activities of Daily Living</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - diagnostic imaging</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer's disease</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain - diagnostic imaging</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Cilostazol - pharmacology</subject><subject>Cilostazol - therapeutic use</subject><subject>Clinical trials</subject><subject>Cognition - drug effects</subject><subject>Cognitive ability</subject><subject>Dementia disorders</subject><subject>Donepezil</subject><subject>Double-Blind Method</subject><subject>Double-blind studies</subject><subject>Female</subject><subject>Frontal gyrus</subject><subject>Glucose - metabolism</subject><subject>Humans</subject><subject>Male</subject><subject>Metabolism</subject><subject>Neurobiology</subject><subject>Neurology</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>Neuropsychological Tests</subject><subject>Neurosciences</subject><subject>Neurosurgery</subject><subject>Original</subject><subject>Original Article</subject><subject>Patients</subject><subject>Phosphodiesterase</subject><subject>Positron emission tomography</subject><subject>Substantia alba</subject><subject>Tomography</subject><subject>Treatment Outcome</subject><subject>White Matter - diagnostic imaging</subject><subject>White Matter - drug effects</subject><subject>White Matter - metabolism</subject><issn>1933-7213</issn><issn>1878-7479</issn><issn>1878-7479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9UcmO1DAUtBCIGQZ-gAOyxIVLwFtimwNSq2kWqREjMYij5SROx6MkbvwcmJ4TN76B3-NLcNPDsBw4eal69apUCN2n5DElRD4ByjmlBaGqyE-iiosb6JgqqQoppL6Z75rzQjLKj9AdgHNCSs61uo2OOJEVLYk-Rl9XXecb2-xw6PDSDwGSvQwDXrSjnzykaJMPE_YTXgyXvfOji9-_fAP83IOz4PBpxt2UAH_2qccfep8cfmNTchGvHeRReIoX-DSATzFMxWr0sP_FZ2EMm2i3_Q6_S3O7u4tudXYAd-_qPEHvX6zOlq-K9duXr5eLddEIKVLhNCXUEkIrRnVd104poZuKta2oRJVj6aqriRJ1zTrteEuJUKK0oqyaruVtw0_Qs4Pudq5H1zbZe7SD2UY_2rgzwXrzNzL53mzCJ1OVpeBKZoFHVwIxfJwdJJMjNW4Y7OTCDIYxlj0qVpJMffgP9TzMccrxDKNSUyl5tWexA6uJASC67toMJWbfszn0bHLP5mfP5iIPPfgzxvXIr2IzgR8IkKFp4-Lv3f-R_QFCjLdT</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Lee, Jun-Young</creator><creator>Lee, Haewoo</creator><creator>Yoo, Hye Bin</creator><creator>Choi, Jung-Seok</creator><creator>Jung, Hee-Yeon</creator><creator>Yoon, Eun Jin</creator><creator>Kim, Hongrae</creator><creator>Jung, Ye-Ha</creator><creator>Lee, Ho-Young</creator><creator>Kim, Yu Kyeong</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190401</creationdate><title>Efficacy of Cilostazol Administration in Alzheimer’s Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study</title><author>Lee, Jun-Young ; Lee, Haewoo ; Yoo, Hye Bin ; Choi, Jung-Seok ; Jung, Hee-Yeon ; Yoon, Eun Jin ; Kim, Hongrae ; Jung, Ye-Ha ; Lee, Ho-Young ; Kim, Yu Kyeong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-e9101a0016219bbbe8849c62dd464630796fb084bb2f9e3d104845a456cfd3dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Activities of Daily Living</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - diagnostic imaging</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer's disease</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain - diagnostic imaging</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Cilostazol - pharmacology</topic><topic>Cilostazol - therapeutic use</topic><topic>Clinical trials</topic><topic>Cognition - drug effects</topic><topic>Cognitive ability</topic><topic>Dementia disorders</topic><topic>Donepezil</topic><topic>Double-Blind Method</topic><topic>Double-blind studies</topic><topic>Female</topic><topic>Frontal gyrus</topic><topic>Glucose - metabolism</topic><topic>Humans</topic><topic>Male</topic><topic>Metabolism</topic><topic>Neurobiology</topic><topic>Neurology</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>Neuropsychological Tests</topic><topic>Neurosciences</topic><topic>Neurosurgery</topic><topic>Original</topic><topic>Original Article</topic><topic>Patients</topic><topic>Phosphodiesterase</topic><topic>Positron emission tomography</topic><topic>Substantia alba</topic><topic>Tomography</topic><topic>Treatment Outcome</topic><topic>White Matter - diagnostic imaging</topic><topic>White Matter - drug effects</topic><topic>White Matter - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Jun-Young</creatorcontrib><creatorcontrib>Lee, Haewoo</creatorcontrib><creatorcontrib>Yoo, Hye Bin</creatorcontrib><creatorcontrib>Choi, Jung-Seok</creatorcontrib><creatorcontrib>Jung, Hee-Yeon</creatorcontrib><creatorcontrib>Yoon, Eun Jin</creatorcontrib><creatorcontrib>Kim, Hongrae</creatorcontrib><creatorcontrib>Jung, Ye-Ha</creatorcontrib><creatorcontrib>Lee, Ho-Young</creatorcontrib><creatorcontrib>Kim, Yu Kyeong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neurotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Jun-Young</au><au>Lee, Haewoo</au><au>Yoo, Hye Bin</au><au>Choi, Jung-Seok</au><au>Jung, Hee-Yeon</au><au>Yoon, Eun Jin</au><au>Kim, Hongrae</au><au>Jung, Ye-Ha</au><au>Lee, Ho-Young</au><au>Kim, Yu Kyeong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of Cilostazol Administration in Alzheimer’s Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study</atitle><jtitle>Neurotherapeutics</jtitle><stitle>Neurotherapeutics</stitle><addtitle>Neurotherapeutics</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>16</volume><issue>2</issue><spage>394</spage><epage>403</epage><pages>394-403</pages><issn>1933-7213</issn><issn>1878-7479</issn><eissn>1878-7479</eissn><abstract>This study tested the efficacy of the phosphodiesterase type III inhibitor cilostazol in Alzheimer’s disease patients with white matter lesions treated with donepezil in comparison with donepezil monotherapy using fluorodeoxyglucose (
18
F) positron-emission tomography (FDG PET). A 24-week, randomized, double-blind, placebo-controlled, parallel-group study was conducted. Thirty-six Alzheimer’s disease patients with white matter lesions who received donepezil (
n
= 18 each in the cilostazol and placebo groups) were enrolled. Participants underwent pre and post FDG PET imaging scans and three rounds of clinical and neuropsychological tests. The cilostazol group did not show a significant decrease of regional glucose metabolism; however, regional glucose metabolism was significantly decreased in the parietal and frontal lobes of the placebo group. The repeated measures ANOVA measuring differences in uptake change revealed that regional glucose metabolism in the left inferior frontal gyrus was significantly more preserved in the cilostazol group than that in the placebo group (
p
< 0.005). Mean changes from baseline on the Mini-Mental State Exam, Alzheimer’s Disease Assessment Scale-cognitive subscale, Alzheimer’s Disease Cooperative Study-Activities of Daily Living Inventory, and the Clinical Dementia Rating Sum of Boxes did not differ between the two groups. In the cilostazol group, the increase of glucose metabolism correlated with the improvment of the Alzheimer’s Disease Assessment Scale-cognitive score. We conclude that cilostazol treatment added to donepezil may delay the decline in regional cerebral metabolism in Alzheimer’s disease with white matter lesions compared with donepezil monotherapy. In additon, our results verified the efficacy of cilostazol in improving or protecting cognitive function in Alzheimer’s disease through increased glucose metabolism. However, the long-term effect of cilostazol on cognitive function and Alzheimer’s disease modification must be tested in further studies with larger sample size and longer study period. Trial registration:
http://clinicaltrials.gov
: NCT01409564</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>30761509</pmid><doi>10.1007/s13311-018-00708-x</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1933-7213 |
| ispartof | Neurotherapeutics, 2019-04, Vol.16 (2), p.394-403 |
| issn | 1933-7213 1878-7479 1878-7479 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6554387 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; SpringerNature Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Activities of Daily Living Aged Aged, 80 and over Alzheimer Disease - diagnostic imaging Alzheimer Disease - drug therapy Alzheimer Disease - metabolism Alzheimer's disease Biomedical and Life Sciences Biomedicine Brain - diagnostic imaging Brain - drug effects Brain - metabolism Cilostazol - pharmacology Cilostazol - therapeutic use Clinical trials Cognition - drug effects Cognitive ability Dementia disorders Donepezil Double-Blind Method Double-blind studies Female Frontal gyrus Glucose - metabolism Humans Male Metabolism Neurobiology Neurology Neuroprotective Agents - pharmacology Neuroprotective Agents - therapeutic use Neuropsychological Tests Neurosciences Neurosurgery Original Original Article Patients Phosphodiesterase Positron emission tomography Substantia alba Tomography Treatment Outcome White Matter - diagnostic imaging White Matter - drug effects White Matter - metabolism |
| title | Efficacy of Cilostazol Administration in Alzheimer’s Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T11%3A42%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20Cilostazol%20Administration%20in%20Alzheimer%E2%80%99s%20Disease%20Patients%20with%20White%20Matter%20Lesions:%20A%20Positron-Emission%20Tomography%20Study&rft.jtitle=Neurotherapeutics&rft.au=Lee,%20Jun-Young&rft.date=2019-04-01&rft.volume=16&rft.issue=2&rft.spage=394&rft.epage=403&rft.pages=394-403&rft.issn=1933-7213&rft.eissn=1878-7479&rft_id=info:doi/10.1007/s13311-018-00708-x&rft_dat=%3Cproquest_pubme%3E2179177360%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2179177360&rft_id=info:pmid/30761509&rfr_iscdi=true |